InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug

Like
Comment
Favorite

InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug

MT Newswires Live01-21

InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.

The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.

ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.

Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2505210109?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-21 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505210109","market":"us","top_or_hot":-1,"title":"InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug","media":"MT Newswires Live","content":"<html><body><p> InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.</p><p>The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.</p><p>ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.</p><p>Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-21 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.</p><p>The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.</p><p>ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.</p><p>Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505210109","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505210109","pubTimestamp":1737448736,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InnoCare Pharma  unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.Beijing InnoCare Pharma Tech and Keymed Biosciences'  unit Keymed Biosciences  each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1161":"生物科技","02162":"康诺亚-B","BK0239":"医药制造","BK6512":"房地产股","BK6004":"海运","BK1574":"生物医药B类股","BK1583":"高瓴概念","09969":"诺诚健华","BK1587":"次新股","5I4.SI":"ICP公司"},"translate_title":"诺诚健华制药部门外包肿瘤药物的生产和商业化许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"02162":1,"09969":0.9,"5I4.SI":0.9},"content_text":"InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}